作者：
Didier,Meulendijks [1]
;
Wolfgang,Jacob [2]
;
Maria,Martinez-Garcia [3]
;
Alvaro,Taus [3]
;
Martijn P,Lolkema [4]
;
Emile E,Voest [1]
;
Marlies H G,Langenberg [5]
;
Tania,Fleitas Kanonnikoff [6]
;
Andres,Cervantes [6]
;
Maja J,De Jonge [7]
;
Stefan,Sleijfer [7]
;
Morten Mau,Soerensen [8]
;
Marlene,Thomas [9]
;
Maurizio,Ceppi [9]
;
Georgina,Meneses-Lorente [10]
;
Ian,James [9]
;
Celine,Adessi [11]
;
Francesca,Michielin [11]
;
Keelara,Abiraj [11]
;
Birgit,Bossenmaier [9]
;
Jan H M,Schellens [1]
;
Martin,Weisser [9]
;
Ulrik N,Lassen [8]
作者单位：
Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
[1]
Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany. wolfgang.jacob@roche.com.
[2]
Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
[3]
Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
[4]
Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
[5]
Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain.
[6]
Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
[7]
Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
[8]
Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
[9]
Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.
[10]
Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
[11]
DOI
10.1158/1078-0432.CCR-15-1683
PMID
26463709
发布时间
2022-04-09
换一批
换一批
